挪威医护人员与普通成年人群SARS-CoV-2 Delta和Omicron感染的疫苗有效性估计,2021年8月至2022年1月
研究基于挪威COVID-19国家预备登记(Beredt C19)数据,采用Cox比例风险模型估计2021年8月1日至2022年1月28日期间医护人员与普通成年人群(18-67岁)针对SARS-CoV-2感染的疫苗有效性。结果显示,医护人员中Delta疫苗有效性为71%,Omicron为19%;非医护人员中Delta为69%,Omicron为-32%。Omicron变异株下第三剂对医护人员的保护(33%)显著优于两剂,非医护人员为10%。
要点
- 医护人员中Delta疫苗有效性为71%,Omicron为19%。
- 非医护人员中Delta为69%,Omicron为-32%。
- Omicron下第三剂对医护人员保护为33%,非医护人员为10%。
核心结论
- Delta变异株下医护人员与非医护人员的疫苗有效性相当,但Omicron变异株下医护人员显著高于非医护人员。
- 医护人员和非医护人员均从第三剂获得增强的保护。
研究设计与样本
- 采用Cox比例风险模型估计疫苗有效性,比较医护人员与普通人群,时间范围为2021年8月1日至2022年1月28日。
- 疫苗状态作为时变协变量,所有模型纳入显式时间并调整年龄、性别、合并症、居住县、出生国和居住条件。
- 数据来自挪威成年人群(18-67岁)和医护人员工作场所数据(截至2021年1月1日登记),均取自COVID-19国家预备登记(Beredt C19)。
主要发现
- 医护人员中疫苗有效性Delta为71%,Omicron为19%。
- 非医护人员中疫苗有效性Delta为69%,Omicron为-32%。
- Omicron变异株下第三剂对医护人员的保护为33%,对非医护人员的保护为10%,均显著优于两剂。
- Omicron变异株下医护人员似乎比非医护人员有更好的疫苗有效性,但Delta变异株下未见此差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health care workers (HCW) have a higher exposure to SARS-CoV-2 virus than other professionals and to protect both HCW and patients, HCW have been prioritized for vaccination against SARS-CoV-2 in many countries. Estimating the COVID-19 vaccine effectiveness among HCW is important to provide recommendations to protect risk groups. METHODS: We estimated vaccine effectiveness against SARS-CoV-2 infections using Cox proportional hazard models among HCW with comparisons in the general population, from 1 August 2021 to 28 January 2022. Vaccine status is specified as a time-varying covariate and all models incorporated explicit time and were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data from the adult Norwegian population (aged 18-67 years) and HCW workplace data (as registered 1 January 2021) were collated from the National Preparedness Register for COVID-19 (Beredt C19). RESULTS: Vaccine effectiveness was higher for Delta than for the Omicron variant in HCW (71 % compared to 19 %) as well as in non-HCW (69 % compared to -32 %). For the Omicron variant a 3rd dose provides significantly better protection against infection than 2 doses in both HCW (33 %) and non-HCW (10 %). Further, HCW seem to have better vaccine effectiveness than non-HCW for the Omicron, but not for the Delta variant. CONCLUSIONS: Vaccine effectiveness were comparable between HCW and non-HCW for the delta variant, but significantly higher in HCW than non-HCW for the omicron variant. Both HCW and non-HCW got increased protection from a third dose.
引用
- Langlete P, Tesli M, Veneti L, et al. Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022. Vaccine. 2023. PMID: 37211454. doi:10.1016/j.vaccine.2023.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。